1.上海中医药大学交叉科学研究院(上海 201203)
2.复旦大学药学院(上海 201203)
3.上海交通大学医学院附属瑞金医院药剂科(上海 200025)
沈逸雯,女,硕士研究生,主要从事抗肿瘤药物研究工作
管滢芸,主管药师;E-mail:gyy40696@rjh.com.cn
扫 描 看 全 文
沈逸雯, 卞会亭, 蒋义鑫, 等. LC-MS/MS同时检测大鼠血浆中千金子抗肿瘤活性成分及其药代动力学研究[J]. 上海中医药杂志, 2021,55(10):46-51.
Yiwen SHEN, Huiting BIAN, Yixin JIANG, et al. Simultaneous determination of antitumor active components of Euphorbiae Semen in rat plasma by LC-MS/MS and its pharmacokinetic study[J]. Shanghai Journal of Traditional Chinese Medicine, 2021,55(10):46-51.
沈逸雯, 卞会亭, 蒋义鑫, 等. LC-MS/MS同时检测大鼠血浆中千金子抗肿瘤活性成分及其药代动力学研究[J]. 上海中医药杂志, 2021,55(10):46-51. DOI: 10.16305/j.1007-1334.2021.2103108.
Yiwen SHEN, Huiting BIAN, Yixin JIANG, et al. Simultaneous determination of antitumor active components of Euphorbiae Semen in rat plasma by LC-MS/MS and its pharmacokinetic study[J]. Shanghai Journal of Traditional Chinese Medicine, 2021,55(10):46-51. DOI: 10.16305/j.1007-1334.2021.2103108.
目的,2,建立灵敏快速的高效液相色谱-串联质谱法(LC-MS/MS),考察千金子中抗肿瘤活性成分大戟因子L2、L3口服(ig)、腹腔注射(ip)和尾静脉注射(iv)给药后在大鼠体内的药代动力学特征。,方法,2,采用 LC-MS/MS内标法测定大戟因子L2、L3血药浓度,流动相为甲醇-水(80:20),色谱柱为BSD Hypersil C,18,柱(100 mm×2.1 mm,3 μm),柱温为30 ℃,体积流量为0.2 mL/min,进样体积为5 μL。质谱条件:电喷雾离子化(ESI)源,正离子模式扫描,多反应监测模式(MRM)检测各有效成分。采用WinNonlin 4.1药动学软件计算药动学参数。,结果,2,大戟因子L2和L3在5~1 000 ng/mL范围内呈现出良好的线性关系(,r,2,>,0.999),提取回收率为90.5%~107.2%,基质效应分别为89.1%~94.2%和88.1%~93.9%,日内、日间精密度 ,RSD,均,<,12.8%。大鼠尾静脉注射大戟因子L2、L3后,C,max,、AUC,0-24 h,分别为(20.76±7.55)、(13.48±4.59)μg/mL和(8.43±2.34)、(5.13±1.38)h·μg,-1,·mL,-1,;大鼠腹腔注射注射大戟因子L2、L3后,C,max,、AUC,0-24 h,分别为(0.95±0.26)、(0.27±0.06)μg/mL和(3.52±0.90)、(0.98±0.29)h·μg,-1,·mL,-1,;口服给药大戟因子L2、L3后,多个样品浓度因低于检测限而未检测到。,结论,2,建立的相关检测方法灵敏、快速、选择性好,可用于大鼠血浆中大戟因子L2、L3的同时测定及其药代动力学研究;药代动力学参数表明,大戟因子L2、L3口服吸收利用度较差,腹腔注射给药相同剂量下大戟因子L2在大鼠体内的暴露量较L3高。
Objective,2,To establish a sensitive and rapid high performance liquid chromatography tandem mass spectrometry (LC-MS/MS) method to investigate the pharmacokinetics of antitumor components (Euphorbia factor L2, L3) after intragastric administration, intraperitoneal injection and intravenous injection in rats.,Methods,2,The plasma concentrations of Euphorbia factors L2 and L3 were determined by LC-MS /MS internal standard method. The mobile phase was methanol-water (80: 20). The chromatographic column was BSD Hypersil C,18, (100 mm × 2.1 mm, 3 μm). The column temperature was 30 ℃, the flow rate was 0.2 mL/min, and the injection volume was 5 μL. Mass spectrometry conditions: electrospray ionization (ESI) source, positive ion mode scanning, multi response monitoring mode (MRM) were used to detect the effective components, and pharmacokinetic parameters were calculated by WinNonlin 4.1 pharmacokinetics software.,Results,2,The good linear range of Euphorbia factors L2 and L3 was 5~1 000 ng/mL (,r,2,>, 0.999). The extraction recoveries ranged from 90.5% to 107.2%. The matrix effects ranged from 89.1% to 94.2% and from 88.1% to 93.9%, respectively. The intra-day and inter-day precisions (RSDs, %) were below 12.8%. C,max, and AUC,0-24 h, after intravenous injection of Euphorbia factor L2 and L3 were (20.76±7.55), (13.48±4.59) μg/mL and (8.43±2.34), (5.13±1.38) h·μg,-1,·mL,-1, respectively; C,max, and AUC,0-24 h, after intraperitoneal injection of Euphorbia factor L2 and L3 were (0.95 ±0.26), (0.27±0.06) μg/mL and (3.52±0.90), (0.98±0.29) h·μg,-1,·mL,-1, respectively. After intragastric administration of Euphorbia factors L2 and L3, the concentrations of several samples were lower than the detection limit and could not be detected.,Conclusion,2,The method is sensitive, rapid and selective, and can be used for the simultaneous determination of Euphorbia factors L2 and L3 in rat plasma and its pharmacokinetics. It showed that the bioavailability of Euphorbia factors L2 and L3 were low after intragastric administration, and the exposure dose of Euphorbia factor L2 was higher than that of L3 in rats after intraperitoneal injection.
大戟因子L2大戟因子L3高效液相色谱-串联质谱法药代动力学抗肿瘤中药研究
Euphorbia factor L2Euphorbia factor L3LC-MS/MSpharmacokinetics antineoplastictraditional Chinese herbal medicine research
刘玉婷,杨洋,弓佩含,等. 千金子化学成分研究进展[J]. 中国实验方剂学杂志,2017, 23(13): 220-225.
国家药典委员会. 中华人民共和国药典(2020版): 一部[M]. 北京:中国医药科技出版社,2020: 36.
胡建平,周东龙,郑进章. 千金子化学成分及药理活性的研究进展综述[J]. 安徽农学通报,2012, 18(7): 45-46.
张瑶,王思,高慧,等. 千金子二萜类成分及其生物活性研究进展[J]. 药物评价研究,2019, 42(12): 2464-2470.
孙国君,张付玉,占扎君,等. 千金子化学成分和药理活性研究进展[J]. 中药材,2010, 33(2): 308-312.
苏晓会. 续随子种子和旋覆花的化学成分研究[D]. 石家庄:河北医科大学,2008.
王丽丽,郭菲,胡乃合,等. 千金子抗肿瘤作用研究进展[J]. 山东中医药大学学报,2016, 40(1): 83-86.
黄晓桃,黄光英,薛存宽,等. 千金子甲醇提取物抗肿瘤作用的实验研究[J]. 肿瘤防治研究,2004, 31(9): 556-557.
王思明,王溪,苏晓会,等. 续随子中千金二萜烷化合物抑制人妇科肿瘤细胞增殖活性的研究[J]. 中国药理学通报,2011, 27(6): 774-776.
冯学花,龚盼盼,宋祖荣. 千金子化学成分及抗癌作用研究进展[J]. 山东化工,2021, 50(9): 64-65.
赵俊峰,李豪,雷震,等. 中药千金子对肾癌Renca细胞凋亡的影响及其机制[J]. 中国老年学杂志,2019, 39(21): 5334-5336.
MENG X, ZHAO X, LONG Z M, et al. A sensitive liquid chromatography-mass spectrometry method for simultaneous determination of three diterpenoid esters from Euphorbia lathyris L. in rat plasma[J]. J Pharm Biomed Anal, 2013(72): 299-305.
0
浏览量
752
下载量
0
CSCD
0
CNKI被引量
关联资源
相关文章
相关作者
相关机构